MorphoSys and G7 Therapeutics sign alliance for GPCR-targeting technology

18 August 2015
2019_biotech_test_vial_discovery_big

German biotech firm MorphoSys (FSE: MOR) and Zurich, Switzerland-based start-up G7 Therapeutics have entered into an agreement to collaborate on novel antibody therapeutics that target G protein-coupled receptors (GPCRs) and potentially other disease-related transmembrane proteins, such as ion channels.

Under the terms of the accord, G7 Therapeutics will generate a set of disease-relevant receptors proposed by MorphoSys. MorphoSys will then apply its proprietary Ylanthia antibody library to discover and develop antibody therapeutics against these receptors. MorphoSys has the right to sub-license third parties with access to these targets in conjunction with therapeutic antibody candidates. No financial terms of the deal were disclosed.

Promising addition to pipeline

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology